[go: up one dir, main page]

MA51431B1 - Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase - Google Patents

Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase

Info

Publication number
MA51431B1
MA51431B1 MA51431A MA51431A MA51431B1 MA 51431 B1 MA51431 B1 MA 51431B1 MA 51431 A MA51431 A MA 51431A MA 51431 A MA51431 A MA 51431A MA 51431 B1 MA51431 B1 MA 51431B1
Authority
MA
Morocco
Prior art keywords
oxy
kinase inhibitor
derivatives used
fluoropiperidine
fluoropiperidine derivatives
Prior art date
Application number
MA51431A
Other languages
English (en)
Other versions
MA51431A (fr
Inventor
Sun Ah Jun
In Woo Kim
Nam Youn Kim
Jun Hee Lee
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of MA51431A publication Critical patent/MA51431A/fr
Publication of MA51431B1 publication Critical patent/MA51431B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un composé représenté par la formule chimique 1 suivante, ou un sel pharmaceutiquement acceptable de celui-ci, et le composé selon la présente invention peut être utilement utilisé pour la prévention ou le traitement de maladies qui sont associées à des actions inhibitrices de kinase.
MA51431A 2017-12-28 2018-12-28 Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase MA51431B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170183061 2017-12-28
PCT/KR2018/016814 WO2019132562A1 (fr) 2017-12-28 2018-12-28 Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase

Publications (2)

Publication Number Publication Date
MA51431A MA51431A (fr) 2021-04-07
MA51431B1 true MA51431B1 (fr) 2022-08-31

Family

ID=67067864

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51431A MA51431B1 (fr) 2017-12-28 2018-12-28 Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase

Country Status (32)

Country Link
US (1) US11339167B2 (fr)
EP (1) EP3733673B1 (fr)
JP (1) JP6995428B2 (fr)
KR (2) KR102318929B1 (fr)
CN (1) CN111527091B (fr)
AU (1) AU2018394997B2 (fr)
BR (1) BR112020013141B1 (fr)
CA (1) CA3084962C (fr)
CL (1) CL2020001752A1 (fr)
CO (1) CO2020007162A2 (fr)
DO (1) DOP2020000112A (fr)
EC (1) ECSP20035590A (fr)
ES (1) ES2922633T3 (fr)
HR (1) HRP20221043T1 (fr)
HU (1) HUE059580T2 (fr)
IL (1) IL275207B (fr)
LT (1) LT3733673T (fr)
MA (1) MA51431B1 (fr)
MX (1) MX2020006799A (fr)
MY (1) MY194468A (fr)
NZ (1) NZ764644A (fr)
PE (1) PE20201146A1 (fr)
PH (1) PH12020551013A1 (fr)
PL (1) PL3733673T3 (fr)
PT (1) PT3733673T (fr)
RS (1) RS63515B1 (fr)
RU (1) RU2758370C1 (fr)
SA (1) SA520412335B1 (fr)
SG (1) SG11202004917UA (fr)
SI (1) SI3733673T1 (fr)
TN (1) TN2020000082A1 (fr)
WO (1) WO2019132562A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018312349A1 (en) 2017-08-01 2020-02-06 Theravance Biopharma R&D Ip, Llc Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
MX2020006799A (es) * 2017-12-28 2020-09-03 Daewoong Pharmaceutical Co Ltd Derivados de oxi-fluoropiperidina como inhibidor de cinasa.
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020154350A1 (fr) 2019-01-23 2020-07-30 Theravance Biopharma R&D Ip, Llc Imidazo[1,5-a]pyridine,1,2,4-triazolo[4,3-a]pyridine et imidazo[1,5-a]pyrazine utilisées en tant qu'inhibiteurs de jak
EP4065578A1 (fr) 2019-11-26 2022-10-05 Theravance Biopharma R&D IP, LLC Composés de pyrimidine pyridinone fusionnés en tant qu'inhibiteurs de jak
CN115023428B (zh) * 2020-01-21 2025-04-08 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN115244055B (zh) * 2020-01-21 2024-09-03 江苏先声药业有限公司 嘧啶并五元环类衍生物及其应用
TW202214643A (zh) * 2020-09-22 2022-04-16 大陸商江蘇先聲藥業有限公司 嘧啶并吡咯類化合物
CN114315838B (zh) * 2020-09-30 2024-09-03 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2023165562A1 (fr) * 2022-03-02 2023-09-07 南京明德新药研发有限公司 Composé hétérocyclique contenant de l'azote et son utilisation
CN116768908B (zh) * 2022-03-10 2025-11-18 石家庄迪斯凯威医药科技有限公司 一种含n多环化合物及其制备方法与用途
WO2025121899A1 (fr) * 2023-12-05 2025-06-12 주식회사 대웅제약 Procédé de préparation de 1-((3s,4r)-3-((2-((1-éthyl-1h-pyrazol-4-yl)amino)-7h-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropipéridin-1-yl)prop-2-én-1-one, et composés intermédiaires de ceux-ci
TW202535367A (zh) * 2023-12-05 2025-09-16 南韓商大熊製藥股份有限公司 1-((3S,4R)-3-((2-((1-乙基-1H-吡唑-4-基)胺基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧基)-4-氟哌啶-1-基)丙-2-烯-1-酮之磷酸鹽、其結晶形式及其製備方法
WO2025121903A1 (fr) * 2023-12-05 2025-06-12 주식회사 대웅제약 Sel de tartrate de 1-((3s,4r)-3-((2-((1-éthyl-1h-pyrazol-4-yl)amino)-7h-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropipéridin-1-yl)prop-2-en-1-one, forme cristalline de celui-ci et procédé de préparation associé

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
WO2009026107A1 (fr) * 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Inhibiteurs de protéine kinases
NZ588830A (en) 2008-04-22 2012-11-30 Portola Pharm Inc Inhibitors of protein kinases
AU2009270856B2 (en) 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
LT2585470T (lt) 2010-06-23 2017-04-10 Hanmi Science Co., Ltd. Nauji kondensuoti pirimidino dariniai tirozino kinazės aktyvumo slopinimui
PE20141228A1 (es) 2011-09-22 2014-10-01 Pfizer Derivados de pirrolopirimidina y purina
KR102181365B1 (ko) 2012-08-06 2020-11-23 에이시아 바이오사이언시스 인코포레이티드. 단백질 키나아제 억제제로서 새로운 피롤로피리미딘 화합물
US9346812B2 (en) 2013-01-16 2016-05-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
KR20150113195A (ko) 2013-03-05 2015-10-07 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
CA2924362C (fr) 2013-09-18 2018-12-18 Beijing Hanmi Pharmaceutical Co., Ltd. Compose inhibiteur d'activites de kinase de btk et/ou de jak3
MD4649C1 (ro) 2013-12-05 2020-04-30 Pfizer Inc. Pirol[2,3-d]pirimidinil, pirol[2,3-b]pirazinil şi pirol[2,3-d]piridinil acrilamide
WO2016000615A1 (fr) 2014-07-02 2016-01-07 Sunshine Lake Pharma Co., Ltd. Composés hétéroaryles et leurs applications pharmaceutiques
CN105732637B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
WO2017106771A1 (fr) 2015-12-16 2017-06-22 Southern Research Institute Composés de pyrrolopyrimidine, leur utilisation à titre d'inhibiteurs de la kinase lrrk2, et leurs procédés de préparation
EP3478687B1 (fr) 2016-06-30 2024-03-20 Daewoong Pharmaceutical Co., Ltd. Dérivés de pyrazolopyrimidine comme inhibiteurs de kinase
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
MX2020006799A (es) * 2017-12-28 2020-09-03 Daewoong Pharmaceutical Co Ltd Derivados de oxi-fluoropiperidina como inhibidor de cinasa.
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체

Also Published As

Publication number Publication date
RU2758370C1 (ru) 2021-10-28
KR20210062618A (ko) 2021-05-31
PH12020551013A1 (en) 2021-08-16
CN111527091A (zh) 2020-08-11
SI3733673T1 (sl) 2022-09-30
CN111527091B (zh) 2023-03-28
DOP2020000112A (es) 2020-08-31
CO2020007162A2 (es) 2020-06-19
EP3733673B1 (fr) 2022-06-29
MA51431A (fr) 2021-04-07
KR102318929B1 (ko) 2021-10-28
HUE059580T2 (hu) 2022-11-28
JP2021506818A (ja) 2021-02-22
LT3733673T (lt) 2022-08-10
TN2020000082A1 (en) 2022-01-06
NZ764644A (en) 2023-06-30
WO2019132562A1 (fr) 2019-07-04
PL3733673T3 (pl) 2022-09-26
MY194468A (en) 2022-11-30
KR20190080803A (ko) 2019-07-08
HRP20221043T1 (hr) 2022-11-11
RS63515B1 (sr) 2022-09-30
KR102592083B1 (ko) 2023-10-20
MX2020006799A (es) 2020-09-03
EP3733673A1 (fr) 2020-11-04
AU2018394997A1 (en) 2020-06-11
SA520412335B1 (ar) 2022-09-19
SG11202004917UA (en) 2020-06-29
PE20201146A1 (es) 2020-10-26
IL275207B (en) 2022-09-01
IL275207A (en) 2020-07-30
BR112020013141B1 (pt) 2022-03-15
CA3084962A1 (fr) 2019-07-04
EP3733673A4 (fr) 2021-06-09
CL2020001752A1 (es) 2020-11-27
ECSP20035590A (es) 2020-07-31
ES2922633T3 (es) 2022-09-19
BR112020013141A2 (pt) 2021-02-23
US11339167B2 (en) 2022-05-24
PT3733673T (pt) 2022-07-18
JP6995428B2 (ja) 2022-01-14
AU2018394997B2 (en) 2021-02-04
US20200308177A1 (en) 2020-10-01
CA3084962C (fr) 2022-08-09

Similar Documents

Publication Publication Date Title
MA51431B1 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
MA52948B1 (fr) Composés
MY196572A (en) Amino-Methyl Piperidine Derivative as Kinase Inhibitor
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA46337B1 (fr) Composé de pyridine
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA47469B1 (fr) Dérivés 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol et composés similaires en tant q'inhibiteurs prs pour le traitement du cancer
PH12021550743A1 (en) Boron containing pde4 inhibitors
PH12021550554A1 (en) N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
MA39983A (fr) Dérivés de carboxamide
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
MA43231B1 (fr) Bloqueur des canaux sodiques
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
MA46965B1 (fr) Modulateurs de gamma ror (rory)
PH12021550258A1 (en) Cdk8/19 inhibitors
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
MA44383B1 (fr) Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer
EA202190690A1 (ru) Борсодержащие ингибиторы pde4
MA45855B1 (fr) Nouvelle utilisation du n, n-bis-2-mercaptoéthyle isophtalamide
NZ748746A (en) Pyrazolopyrimidine derivatives as kinase inhibitor
MA50899B1 (fr) Composés utiles pour l'inhibition de cdk7
EA201992397A1 (ru) Соединения для лечения эпилепсии, нейродегенеративных нарушений и других нарушений цнс